Vascular Disorders

Published on 25/03/2015 by admin

Filed under Pediatrics

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 2878 times

Chapter 642 Vascular Disorders

Vascular lesions of childhood may be divided into vascular birthmarks (malformations and tumors), benign acquired disorders, and genetic diseases. Familial disorders may involve arterial, capillary, lymph, or venous malformations (Table 642-1).

Vascular Malformation

Vascular malformations are developmental errors in blood vessel formation. Malformations do not regress but slowly enlarge. They should be named after the predominant blood vessel forming the lesion (Table 642-2). Table 642-3 helps differentiate vascular malformations from true hemangiomas.

Table 642-2 VASCULAR MALFORMATIONS

TYPE EXAMPLE(S)
Capillary Port-wine stain
Venous Venous malformation
Angiokeratoma circumscriptum (hyperkeratotic venule)
Cutis marmorata telangiectasia congenita (congenital phlebectasia)
Arterial Arteriovenous malformation
Lymphatic Superficial lymphatic malformation (lymphangioma circumscriptum)
Deep lymphatic malformation with macrocysts and/or microcysts (cystic hygroma)

Table 642-3 MAJOR DIFFERENCES BETWEEN HEMANGIOMAS AND VASCULAR MALFORMATIONS

  HEMANGIOMAS VASCULAR MALFORMATIONS (CAPILLARY, VENOUS, LYMPHATIC, ARTERIAL, AND ARTERIOVENOUS, PURE, OR COMPLEX-COMBINED)
Clinical Variably visible at birth Usually visible at birth (AVMs may be quiescent)
Subsequent rapid growth Growth proportionate to the skin’s growth (or slow progression); present lifelong
Slow, spontaneous involution  
Sex ratio F:M 3 : 1 to 5 : 1; 7 : 1 in severe cases 1 : 1
Pathology Proliferating stage: hyperplasia of endothelial cells and smooth muscle cell actin–positive cells Flat endothelium
Multilaminated basement membrane Thin basement membrane
Higher mast cell content in involution Often irregularly attenuated walls (VM, LM)
Radiology Fast-flow lesion on Doppler sonography Slow flow (CM, LM, VM) or fast flow (AVM) on Doppler ultrasonography
Tumoral mass with flow voids on MRI MRI: Hyperintense signal on T2-weighted images when slow-flow (LM, VM); flow voids on T1- and T2-weighted images when fast-flow (AVM)
Lobular tumor on arteriogram Arteriography of AVM demonstrates AV shunting
Bone changes Rarely mass effect with distortion but no invasion Slow-flow VM: distortion of bones, thinning, underdevelopment
Slow-flow CM: hypertrophy
Slow-flow LM: distortion, hypertrophy, and invasion of bones
High-flow AVM: destruction, rarely extensive lytic lesions
Combined malformations (e.g., slow-flow [capillary lymphatic venous malformation, Klippel-Trenaunay syndrome] or fast-flow [capillary arteriovenous malformation Parkes-Weber syndrome]): overgrowth of limb bones, gigantism
Immunohistochemistry on tissue samples Proliferating hemangioma: high expression of PCNA, type IV collagenase, VEGF, urokinase, and bFGF, Glucose transporter-1

Involuting hemangioma: high levels of tissue inhibitor of metalloproteinase-1, bFGF   Hematology No coagulopathy (Kasabach-Merritt syndrome is a complication of other vascular tumors of infancy, e.g., kaposiform hemangioendothelioma and tufted angioma) Slow-flow VM, LM, or LVM may have an associated localized intravascular coagulopathy with risk of bleeding (disseminated intravascular coagulation)

AVM, Arteriovenous malformation; bFGF, basic fibroblast growth factor; CM, capillary malformation/port-wine stain; LM, lymphatic malformation; LVM, lymphovenous malformation; PCNA, proliferating cell nuclear antigen; VEGF, vascular endothelial growth factor; VM, venous malformation.

From Eichenfield LF, Frieden IJ, Esterly NB: Textbook of neonatal dermatology, Philadelphia, 2001, WB Saunders, p 337.

Capillary Malformation (Port-Wine Stain)

Port-wine stains are present at birth. These vascular malformations consist of mature dilated dermal capillaries. The lesions are macular, sharply circumscribed, pink to purple, and tremendously varied in size (Fig. 642-1). The head and neck region is the most common site of predilection; most lesions are unilateral. The mucous membranes can be involved. As a child matures into adulthood, the port-wine stain may become darker in color and pebbly in consistency; it may occasionally develop elevated areas that bleed spontaneously.

True port-wine stains should be distinguished from the most common vascular malformation, the salmon patch of neonates, which, in contrast, is a relatively transient lesion (Chapter 639). When a port-wine stain is localized to the trigeminal area of the face, specifically around the eyelids, the diagnosis of Sturge-Weber syndrome (glaucoma, leptomeningeal venous angioma, seizures, hemiparesis contralateral to the facial lesion, intracranial calcification) must be considered (Chapter 589.3). Early screening for glaucoma is important to prevent additional damage to the eye. Port-wine stains also occur as a component of Klippel-Trenaunay syndrome and with moderate frequency in other syndromes, including Cobb (spinal arteriovenous malformation, port-wine stain), Proteus, Beckwith-Wiedemann, and Bonnet-Dechaume-Blanc syndromes. In the absence of associated anomalies, morbidity from these lesions may include a poor self-image, hypertrophy of underlying structures, and traumatic bleeding.

The most effective treatment for port-wine stains is with the pulsed dye laser (PDL). This therapy is targeted to hemoglobin within the lesion and avoids thermal injury to the surrounding normal tissue. After such treatment, the texture and pigmentation of the skin are generally normal without scarring. Therapy can begin in infancy, when the surface area of involvement is smaller; there may be advantages to treating within the 1st year of life. Although this approach is quite effective, redarkening of the stain may occur 10 yr after therapy. Masking cosmetics may also be used.

Venous Malformation

Venous malformations include vein-only malformation, angiokeratomas (hyperkeratotic venule), and cutis marmorata telangiectasia congenita.

Malformations consisting of veins only run the gamut from nodules containing a mass of venules (Fig. 642-2) to diffuse large vein abnormalities that may consist of either a superficial component resembling varicose veins, deeper venous malformations, or both. Nodular venous malformations are frequently confused with hemangiomas. Venous malformations may be differentiated by their presence at birth, lack of rapid growth phase, and no tendency toward regression. The treatment of choice for superficial nodular vascular malformations is surgical excision. Treatment of larger vein malformations is at best difficult and often impossible. Percutaneous sclerotherapy with direct injection of polidocanol microfoam, with color Doppler ultrasonographic guidance, is helpful in many patients, including those with Klippel-Trenaunay syndrome.

Cutis Marmorata Telangiectatica Congenita (Congenital Phlebectasia)

Cutis marmorata telangiectatica congenita is benign vascular anomaly that represents dilatation of superficial capillaries and veins and is apparent at birth. Involved areas of skin have a reticulated red or purple hue that resembles physiologic cutis marmorata but is more pronounced and relatively unvarying (Fig. 642-3). The lesions may be restricted to a single limb and a portion of the trunk or may be more widespread. Port-wine stain may also be associated. The lesions become more pronounced during changes in environmental temperature, physical activity, or crying. In some cases, the underlying subcutaneous tissue is underdeveloped, and ulceration may occur within the reticulated bands. Rarely, defective growth of bone and other congenital abnormalities may be present. No specific therapy is indicated. Mild vascular-only cases may show gradual improvement. Adams-Oliver syndrome and cutis marmorata telangiectatica congenita–macrocephaly syndrome are rarely associated disorders.

Klippel-Trenaunay and Klippel-Trenaunay-Weber Syndromes

Klippel-Trenaunay syndrome (KT) is a cutaneous vascular malformation that, in combination with bony and soft tissue hypertrophy and venous abnormalities, constitutes the triad of defects of this nonheritable disorder (Fig. 642-5). The anomaly is present at birth and usually involves a lower limb but may involve more than one as well as portions of the trunk or face. Enlargement of the soft tissues may be gradual and may involve the entire extremity, a portion of it, or selected digits. The vascular lesion most often is a capillary malformation, generally localized to the hypertrophied area. The deep venous system may be absent or hypoplastic. Venous blebs and/or vesicular lymphatic lesions may be present on the malformation’s surface. Thick-walled venous varicosities typically become apparent ipsilateral to the vascular malformation after the child begins to ambulate. If there is an associated AVM, the disorder is called Klippel-Trenaunay-Weber syndrome (KTW).

These disorders can be confused with Maffucci syndrome or, if the surface vascular lesion is minimal, with Milroy disease. Pain, limb swelling, and cellulitis may occur. Thrombophlebitis, dislocations of joints, gangrene of the affected extremity, heart failure, hematuria secondary to angiomatous involvement of the urinary tract, rectal bleeding from lesions of the gastrointestinal tract, pulmonary lesions, and malformations of the lymphatic vessels are infrequent complications. Arteriograms, venograms, and CT or MRI may delineate the extent of the anomaly, but surgical correction or palliation is often difficult. Percutaneous sclerotherapy guided by color echo Doppler ultrasonography is of benefit when a venous component is the dominant vessel in the malformation. The indications for radiologic studies of viscera and bones are best determined by clinical evaluation. Supportive care includes compression bandages for varicosities; surgical treatment may help carefully selected patients. Leg-length differences should be treated with orthotic devices to prevent the development of spinal deformities. Corrective bone surgery may eventually be needed to treat significant leg-length discrepancy.

Vascular Tumor

Vascular tumors include hemangiomas (the most common tumor of childhood), tufted angiomas, kaposiform hemangioendotheliomas, rapidly involuting congenital hemangiomas (RICHs), and non-involuting congenital hemangiomas (NICHs).

Hemangioma

Hemangiomas are proliferative hamartomas of vascular endothelium that may be present at birth or, more commonly, may become apparent in the 1st 2 mo of life, predictably enlarge, and then spontaneously involute. Hemangiomas are the most common tumor of infancy, occurring in 1-2% of newborns (higher in preterm infants) and 10% of white infants in the 1st year of life. Hemangiomas should be classified as superficial, deep, or mixed. The terms strawberry and cavernous should not be used to describe hemangiomas. The immunohistochemical marker GLUT-1 separates hemangiomas from the other vascular tumors of infancy. Superficial hemangiomas are bright red, protuberant, compressible, sharply demarcated lesions that may occur on any area of the body (Figs. 642-6 and 642-7). Although sometimes present at birth, they more often appear in the 1st two months of life and are heralded by an erythematous or blue mark or an area of pallor, which subsequently develops a fine telangiectatic pattern before the phase of expansion. The presenting sign may occasionally be an ulceration of the perineum or lip. Girls are affected more often than boys. Favored sites are the face, scalp, back, and anterior chest; lesions may be solitary or multiple. Patterns of facial involvement include frontotemporal, maxillary, mandibular, and frontonasal regions. Hemangiomas that are more deeply situated are more diffuse and are less defined than superficial hemangiomas. The lesions are cystic, firm, or compressible, and the overlying skin may appear normal in color or may have a bluish hue (Fig. 642-8).

Most hemangiomas are mixed, having both superficial and deep components. Hemangiomas undergo a phase of rapid expansion, followed by a stationary period and finally by spontaneous involution. Regression may be anticipated when the lesion develops blanched or pale gray areas that indicate fibrosis. The course of a particular lesion is unpredictable, but ≈ 60% of these lesions reach maximal involution by 5 yr of age, and 90-95% by 9 yr. Spontaneous involution cannot be correlated with size or site of involvement, but lip lesions seem to persist most often. Complications include ulceration, secondary infection, and, rarely, hemorrhage (Table 642-4). The location of a lesion may interfere with a vital function (e.g., on eyelid interfering with vision, on urethra with urination, on airway with respiration). Hemangiomas in a “beard” distribution may be associated with upper airway or subglottic involvement. Respiratory symptoms should suggest a tracheobronchial lesion. Large hemangiomas may be complicated by coexistent hypothyroidism due to type 3 iodothyronine deiodinase, and symptoms may be difficult to detect in this age group. Other concerning features are listed in Table 642-5.

Table 642-4 COMPLICATIONS OF HEMANGIOMA AND THEIR TREATMENT

CLINICAL FINDING RECOMMENDED TREATMENT
Severe ulceration/maceration Encourage twice-daily cleansing regimen
Dilute sodium bicarbonate soaks
± Flashlamp pulsed dye laser
± Oral corticosteroids or propranolol
± Culture-directed systemic antibiotics for infection
Bleeding (not KMP) Gelfoam or Surgifoam or propranolol
Compression therapy ± embolization
Hemangioma with ophthalmologic sequelae Patching therapy as directed by ophthalmologist
Intralesional vs oral corticosteroids vs propranolol
Subglottic hemangioma Oral corticosteroids ± potassium titanyl phosphate (KtP) laser
Tracheotomy if required
KMP Corticosteroids, aminocaproic acid, vincristine, interferon-α ± embolization
High-flow hepatic hemangioma Corticosteroids or interferon ± embolization

KMP, Kasabach-Merritt phenomenon.

From Blei F: Vascular anomalies: from bedside to bench and back again, Curr Prob Pediatr Adolesc Health 32:72–93, 2002.

Table 642-5 CLINICAL “RED FLAGS” ASSOCIATED WITH HEMANGIOMAS

CLINICAL FINDING RECOMMENDED EVALUATION
Facial hemangioma involving significant area of face Evaluate for PHACES (posterior fossa abnormalities, hemangioma, and arterial, cardiac, eye, and sternal abnormalities): MRI for orbital hemangioma ± posterior fossa malformation
Cardiac, ophthalmologic evaluation
Evaluate for midline abnormality: supraumbilical raphe, sternal atresia, cleft palate, thyroid abnormality
Cutaneous hemangiomas in beard distribution Evaluate for airway hemangioma, especially if manifesting with stridor
Periocular hemangioma

Paraspinal midline vascular lesion Ultrasonography or MRI to evaluate for occult spinal dysraphism Hemangiomatosis (multiple small cutaneous hemangiomas)

Large hemangioma, especially hepatic Ultrasonongraphy with Doppler flow study MRI Thyroid function studies Thrill and/or bruit associated with hemangioma Consider cardiac evaluation and echocardiography to rule out diastolic reversal of flow in aorta MRI to evaluate extent and flow characteristics Head tilting Evaluate appropriately for specific site of lesion, and consider physical therapy evaluation Delayed milestones Consider side effect of corticosteroids (myopathy, weight-related) Consider side effect of interferon (especially spastic diplegia)

From Blei F: Vascular anomalies: from bedside to bench and back again, Curr Prob Pediatr Adolesc Health 32:67–102, 2002.

In the usual patient with a hemangioma who has no serious complications or extensive growth resulting in tissue destruction and severe disfigurement, treatment consists of expectant observation. Because almost all lesions regress spontaneously, therapy is rarely indicated and may cause further harm. Parents require repeated reassurance and support. After spontaneous involution, many patients are left with small cosmetic defects, such as telangiectasia, hypopigmentation, fibrofatty deposits, and scars if the lesion has ulcerated. Residual telangiectasias may be treated with PDL therapy. Other defects can be treated or minimized by judicious plastic repair if desired.

In the rare case in which intervention is required, if the lesion is very superficial, early therapy with PDL may be beneficial in decreasing growth of the hemangioma. PDL is also useful for the treatment of small (<4-5 cm) ulcerated hemangiomas. Elastic bandages may reduce the amount of tissue distortion resulting from rapid growth, but they are appropriate only in selected patients with large hemangiomas. Rarely, these lesions impinge on vital structures; interfere with functions such as vision, breathing, defecation, urination, or feeding; or cause grotesque disfigurement because of rapid growth.

If further treatment becomes necessary, a course of prednisolone (2-3 mg/kg/24 hr) is effective in most infants. Termination of growth and sometimes regression may be evident after ≈ 2-4 wk of therapy. When a response is obtained, the dose should be decreased gradually. Intralesional corticosteroid injection in the hands of an experienced physician can also induce rapid involution of a localized hemangioma. Propranolol (2 mg/kg) has been used for hemangiomas unresponsive to corticosteroid therapy. Results have been excellent, but exact indications for usage, dosage, length of treatment, and long-term sequelae have not been thoroughly investigated. Hypoglycemia may be a complication of propranolol therapy. Vincristine is used by some oncologists to treat significant hemangiomas. Interferon-α (IFN-α) therapy may also be effective, but spastic diplegia is seen in 10% of cases.

Syndromes associated with hemangiomas include PHACES (posterior fossa brain defects such as Dandy-Walker malformation or cerebellar hypoplasia, large plaquelike facial hemangioma, arterial cerebrovascular abnormalities such as aneurysms and stroke, coarctation of the aorta, eye abnormalities, and sternal raphe defects such as pits, scars, or supraumbilical raphe), Gorham (cutaneous hemangiomas with massive osteolysis), and Bannayan-Riley-Ruvalcaba (macrocephaly lipomas, hemangiomas of autosomal dominant inheritance).

Diffuse Hemangiomatosis

Diffuse hemangiomatosis is a condition in which numerous hemangiomas are widely distributed. The skin usually has many small red papular hemangiomas (Fig. 642-9). Most affected infants have benign neonatal hemangiomatosis, with widespread cutaneous hemangiomas in the absence of apparent visceral involvement. Diffuse neonatal hemangiomatosis is the association of multiple cutaneous hemangiomas of the skin with similar lesions in internal organs. The internal hemangiomas may involve any of the viscera; the liver, gastrointestinal tract, central nervous system, and lungs are the most common sites. In cases of benign neonatal hemangiomatosis, spontaneous regression of the lesions without complications is probable. Infants with diffuse neonatal hemangiomatosis are usually ill at birth. In these cases, ultrasonography and CT are indicated to determine the extent of visceral or neural involvement. The disorder is often fatal because of high-output cardiac failure, visceral hemorrhage, obstruction of the respiratory tract, or compression of central neural tissue. Treatment consists of systemic corticosteroid therapy alone or in combination with vincristine, IFN-α, surgery, or irradiation and support with blood products for erythrocyte, platelet, and coagulation factor consumption.

image

Figure 642-9 Disseminated cutaneous (and liver) neonatal hemangiomatosis.

(From Eichenfield LF, Frieden IJ, Esterly NB: Textbook of neonatal dermatology, ed 2, Philadelphia, 2008, Saunders, p 359.)

Kasabach-Merritt Syndrome

Kasabach-Merritt syndrome is a life-threatening combination of a rapidly enlarging tufted angioma or kaposiform hemangioendothelioma, thrombocytopenia, microangiopathic hemolytic anemia, and an acute or chronic consumption coagulopathy. The clinical manifestations are usually evident during early infancy. The vascular lesion is usually cutaneous and is only rarely located in viscera. The associated thrombocytopenia may lead to precipitous hemorrhage accompanied by ecchymoses, petechiae, and a rapid increase in the size of the vascular lesion. Severe anemia due to hemorrhage or microangiopathic hemolysis may ensue. The platelet count is depressed, but the bone marrow contains increased numbers of normal or immature megakaryocytes. The thrombocytopenia has been attributed to sequestration or increased destruction of platelets within the lesion. Hypofibrinogenemia and decreased levels of consumable clotting factors are relatively common (Chapter 478.6).

Treatment involves management of thrombocytopenia, anemia, and consumptive coagulopathy by administration of platelets and by transfusion of red blood cells and fresh frozen plasma. The use of heparinization in this syndrome is controversial but has benefited some patients when combined with transfusions. Treatment of Kasabach-Merritt syndrome includes surgical excision of small lesions, systemic steroids, embolization, radiation therapy, vincristine, aminocaproic acid, cyclophosphamide, pentoxifylline, or recombinant IFN-α. The mortality rate is significant.

Benign Acquired Vascular Disorders

Pyogenic Granuloma (Lobular Capillary Hemangioma)

A pyogenic granuloma is a small red, glistening, sessile, or pedunculated papule that often has a discernible epithelial collarette (Fig. 642-11). The surface may be weeping and crusted or completely epithelialized. Pyogenic granulomas initially grow rapidly, may ulcerate, and bleed easily when traumatized because they consist of exuberant granulation tissue. They are relatively common in children, particularly on the face, arms, and hands. Such a lesion located on a finger or hand may appear as a subcutaneous nodule. Pyogenic granulomas may arise at sites of injury, but a history of trauma often cannot be elicited. Clinically, they resemble and are often indistinguishable from small hemangiomas. Microscopically, an early pyogenic lesion resembles an early capillary hemangioma. Collarette formation at the base of the tumor and edema of the stroma may allow differentiation from a capillary hemangioma.

Pyogenic granulomas are benign but a nuisance because they bleed easily with trauma and may recur if incompletely removed. Numerous satellite papules have developed after surgical excision of pyogenic granulomas from the back, particularly in the interscapular region. Small lesions may regress after cauterization with silver nitrate; larger lesions require excision and electrodesiccation of the base of the granuloma. Small (< 5 mm) lesions may be treated successfully with the flashlamp pumped PDL.

Spider Angioma

A vascular spider (nevus araneus) consists of a central feeder artery with many dilated radiating vessels and a surrounding erythematous flush, varying from a few millimeters to several centimeters in diameter (Fig. 642-12). Pressure over the central vessel causes blanching; pulsations visible in larger nevi are evidence for the arterial source of the lesion. Spider angiomas are associated with conditions in which there are increased levels of circulating estrogens, such as cirrhosis and pregnancy, but they also occur in up to 15% of normal preschool-aged children and 45% of school-aged children. Sites of predilection in children are the dorsum of the hand, forearm, face, and ears. Lesions often regress spontaneously after puberty. If removal is desired, PDL is the mode of choice; resolution is achieved in 90% of cases with a single treatment.

Genetic Disorders

Hereditary Hemorrhagic Telangiectasia (Osler-Weber-Rendu Disease)

Hereditary hemorrhagic telangiectasia (HHT), which is inherited as an autosomal dominant trait, occurs in two types. The gene in HHT-1 encodes endoglin, a membrane glycoprotein on endothelial cells that binds transforming growth factor-β. HHT-2 is caused by mutations in the ACVRL1 gene and is associated with increased risk for hepatic involvement and pulmonary hypertension. Affected children may experience recurrent epistaxis before detection of the characteristic skin and mucous membrane lesions. The mucocutaneous lesions, which usually develop at puberty, are 1- to 4-mm, sharply demarcated red to purple macules, papules, or spider-like projections, each composed of a tightly woven mat of tortuous telangiectatic vessels. The nasal mucosa, lips, and tongue are usually involved; less commonly, cutaneous lesions occur on the face, ears, palms, and nail beds. Vascular ectasias may also arise in the conjunctivae, larynx, pharynx, gastrointestinal tract, bladder, vagina, bronchi, brain, and liver.

Massive hemorrhage is the most serious complication of HHT and may result in severe anemia. Bleeding may occur from the nose, mouth, gastrointestinal tract, genitourinary tract, or lungs; epistaxis is often the only complaint, however, occurring in 80% of patients. Approximately 15-20% of patients with AVMs in the lungs present with stroke due to embolic abscesses. Persons with HHT have normal levels of clotting factors and an intact clotting mechanism. In the absence of serious complications, lifespan of a person with HHT is normal. Local lesions may be ablated temporarily with chemical cautery or electrocoagulation. More drastic surgical measures may be required for lesions in critical sites, such as the lung or gastrointestinal tract. Anemia should be treated with iron.

Angiokeratoma Corporis Diffusum (Fabry Disease) (Chapter 80.4)

An inborn error of glycolipid metabolism (α-galactosidase), angiokeratoma corporis diffusum is an X-linked recessive disorder that is fully penetrant in males and is of variable penetrance in carrier females. Angiokeratomas appear before puberty and occur in profusion over the genitalia, hips, buttocks, and thighs and in the umbilical and inguinal regions. They consist of 0.1- to 3-mm red to blue-black papules that may have a hyperkeratotic surface. Telangiectasias are seen in the mucosa and conjunctiva. On light microscopy, these angiokeratomas appear as blood-filled, dilated, endothelium-lined vascular spaces. Granular lipid deposits are demonstrable in dermal macrophages, fibrocytes, and endothelial cells.

Additional clinical manifestations include recurrent episodes of fever and agonizing pain, cyanosis and flushing of the acral limb areas, paresthesias of the hands and feet, corneal opacities detectable on slit-lamp examination, and hypohidrosis. Renal involvement and cardiac involvement are the usual causes of death. The biochemical defect is a deficiency of the lysosomal enzyme α-galactosidase, with accumulation of ceramide trihexoside in tissues, particularly vascular endothelium, and excretion in urine (see Chapter 80.4 for therapy). Similar cutaneous lesions have also been described in another lysosomal enzyme disorder, α-L-fucosidase deficiency, and in sialidosis, a storage disease with neuraminidase deficiency.

Bibliography

Browning JC, Metry DW. Rapidly involuting congenital hemangioma: case report and review of the literature. Dermatol Online J. 2008;15:11.

Chang LC, Haggstrom AN, Drolet BA, et al. Growth characteristic of infantile hemangiomas: implication for management. Pediatrics. 2008;122:360-367.

2008 Claesson-Welsh: Healing hemangiomas. Nature Med. 2008;14:1147-1148.

Dadlani C, Kamino H, Walters RF, et al. Unilateral nevoid telangiectasia. Dermatol Online J. 2008;14:3.

Drolet BA, Chamlin SL, Garzon MC, et al. Prospective study of spinal anomalies in children with infantile hemangiomas of the lumbosacral skin. J Pediatr. 2010;157:789-794.

Drolet BA, Swanson EA, Frieden IJ. Infantile hemangiomas: an emerging health issue linked to an increased rate of low birth weight infants. J Pediatr. 2008;153:712-715.

Fay A, Nguyen J, Waner M. Conceptual approach to the management of infantile hemangiomas. J Pediatr. 2010;157(6):881-888.

Garzon MC, Huang JT, Enjolras O, et al. Vascular malformations: part 1. J Am Acad Dermatol. 2007;56:353-370.

Garzon MC, Huang JT, Enjolras O, et al. Vascular malformations: part 2. J Am Acad Dermatol. 2007;56:541-564.

Guo S, Ni N. Topical treatment for capillary hemangioma of the eyelid using β-blocker solution. Arch Opthalmol. 2010;128(2):255-256.

Huikeshoven M, Koster PHL, de Borgie CAJM, et al. Redarkening of port-wine stains 10 years after pulsed-dye-laser treatment. N Engl J Med. 2007;356:1235-1240.

Iacobas I, Burrows PE, Frieden IJ, et al. LUMBAR: association between cutaneous infantile hemangiomas of the lower body and regional congenital anomalies. J Pediatr. 2010;157:795-801.

Jinnin M, Medici D, Park L, et al. Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nature Med. 2008;14:1236-1246.

Karen JK, Mengden SJ, Kamino H, Shupack JL. Generalized essential telangiectasia. Dermatol Online J. 2008;14:9.

Kelly KM, Choi B, McFarlane S, et al. Description and analysis of treatments for port-wine stains. Arch Facial Plast Surg. 2005;7:287-294.

Leaute-Labreze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for sever hemangiomas of infancy. N Engl J Med. 2008;358:2649-2651.

Limaye N, Wouters V, Uebelhoer M, et al. Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations. Nat Genet. 2009;41:118-124.

Maguiness SM, Hoffman WY, McCalmont TH, et al. Early white discoloration of infantile hemangioma. Arch Dermatol. 2010;14(11):1235-1239.

Mendonca DA, McCafferty I, Nishikawa H, et al. Venous malformations of the limbs: the Birmingham experience, comparisons and classification in children. J Plast Reconstr Aesthet Surg. 2010;63:383-389.

Metry DW, Haggstrom AN, Drolet BA, et al. A prospective study of PHACE syndrome in infantile hemangiomas: demographic features, clinical findings, and complications. Am J Med Genet. 2006;140:975-986.

Metry D, Heyer G, Hess C, et al. Consensus statement on diagnostic criteria for PHACE syndrome. Pediatrics. 2009;124(5):1447-1456.

North PE, Waner M, Buckmiller L, et al. Vascular tumors of infancy and childhood: beyond capillary hemangioma. Cardiovasc Pathol. 2006;15:303-317.

Pavlaković H, Kietz S, Lauerer P, et al. Hyperkalemia complicating propranolol treatment of an infantile hemangioma. Pediatrics. 2010;126(6):e1589-e1593.

Pope E, Krafchik BR, Macarthur C, et al. Oral versus high-dose pulse corticosteroids for problematic infantile hemangiomas: a randomized, controlled trial. Pediatrics. 2007;119:e1239-e1247.

Saint-Jean M, Léauté-Labreze C, Mazereeuw-Hautier J, et al. Propranolol for treatment of ulcerated infantile hemangiomas. J Am Acad Dermatol. 2011;64(5):827-832.

Siegfried EC, Keenan WJ, Al-Jureidini S. More on propranolol for hemangiomas of infancy. N Engl J Med. 2008;359:2846-2847.

Tan ST, Itinteang T, Leadbitter P. Low-dose propranolol for multiple hepatic and cutaneous hemangiomas with deranged liver function. Pediatrics. 2011;127:e772-e776.